富祥股份(300497.SZ)擬以債轉股方式向江西祥太增資1.649億元
格隆匯2月5日丨富祥股份(300497.SZ)公佈,公司於2020年2月4日召開第三屆董事會第九次會議審議通過了《關於向全資子公司增資的公告》,根據公司發展規劃和全資子公司江西祥太生命科學有限公司(“江西祥太”)實際經營情況,公司擬以債轉股的方式對江西祥太增資1.649億元人民幣,此次增資完成後,江西祥太註冊資本由人民幣1180萬元增加至人民幣1.767億元。
江西祥太生命科學有限公司經營範圍:生命科學儀器研發,醫學研究和試驗發展,原料藥製造、銷售(憑藥品生產許可證經營);化工原料(不含化學危險品)製造、銷售;經營進出口業務。(依法須經批准的項目,經相關部門批准後方可開展經營活動)。
鑑於江西祥太為公司募投項目“高品質他唑巴坦建設項目”、“藥物研發中心建設項目”的實施主體,根據募投項目進展情況,公司分次從募集專户累計撥付了人民幣1.649億元的募集資金投入至募投項目中。公司將對該部分募集資金形成的債權人民幣1.649億元以人民幣1元/註冊資本的價格轉作對江西祥太的長期股權投資資本金,形成註冊資本。
此次增資事項,有利於募投項目順利實施,進一步優化公司及江西祥太的資本結構;能提升江西祥太的市場競爭力,有利於業務拓展;也符合公司發展戰略,能提升公司綜合競爭力。此次增資不存在改變或變相改變募集資金用途的情形,不存在損害公司利益及股東利益的情形,不會對公司現有財務結構及經營狀況產生不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.